ArticleBriefings in bioinformatics2026
Revealing shared molecular markers and mechanisms in colorectal cancer and COVID-19 through bioinformatics and machine learning.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potentially Functional Variants in FCER1A and PLCG2, Two B Cell-Related Immune Genes Predict the Survival of Chinese Gastric Cancer Patients.Molecular carcinogenesis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Colorectal cancer (CRC) and Coronavirus Disease 2019 (COVID-19) are distinct diseases that may share overlapping molecular mechanisms, particularly in immune dysregulation. However, the specific regulatory pathways driving this shared pathophysiology have remained elusive, as prior studies have been limited by single-level data. To dissect this common pathobiology, we implemented a synergistic computational framework, integrating bulk transcriptomics with single-cell data. Through a multi-tiered analysis pipeline employing differential expression, weighted gene co-expression networks, and machine learning-based feature selection, we pinpointed a core molecular signature of 31 shared hub genes. Among these, four core candidates-GPR15, PTGDR2, FCER1A, and MAL-were significantly downregulated, a finding robustly associated with impaired CD8+ T cell infiltration. Delving deeper into the regulatory architecture using a modified weighted out-degree centrality algorithm, we constructed an integrated transcription factor-microRNA-target network. Network analysis revealed upregulation of p53 and downregulation of miR-3619-5p as possible drivers of immune dysfunction. Finally, E-4031 was identified through molecular simulation as a potential therapeutic agent targeting all four core genes. These findings uncover a shared regulatory axis involving immune suppression and transcriptional disruption, and provide promising diagnostic and therapeutic targets for CRC and COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.